检索结果-南通市图书馆

Modular micro-PCR system for the onsite rapid diagnosis of COVID-19

Microsystems & Nanoengineering 2022年第4期8卷 125-136页

作者： Phuong Quoc Mai Nguyen Ming Wang Nelisha Ann Maria Adelicia Yongling Li Hsih Yin Tan gordon minru x.ong Meng-Kwang Marcus Tan Ali Asgar S.Bhagat Catherine W.M.ong Chwee Teck Lim Institute for Health Innovation and Technology(iHealthtech) National University of SingaporeMD614 Medical Drive#14-01Singapore 117599Singapore Department of Biomedical Engineering National University of Singapore4 Engineering Drive 3Block 4#04-08Singapore 117583Singapore Advanced MedTech 2 Venture Drive#23-18 Vision ExchangeSingapore 608526Singapore Infectious Diseases Translational Research Programme Department of MedicineYong Loo Lin School of MedicineNational University of SingaporeNUHS Tower Block1E Kent Ridge Road Level 11Singapore 119228Singapore

Effective containment of the COVID-19 pandemic requires rapid and accurate detection of the *** chain reaction(PCR)remains the gold standard for COVID-19 *** this article,we report the performance of a cost-effective modular microfluidic reverse transcription(RT)-PCR and RT-loop mediated isothermal amplification(RTLAMP)platform,Epidax®,for the point-of-care testing and confirmation of *** platform is versatile and can be reconfigured either for screening using endpoint RT-PCR or RT-LAMP tests or for confirmatory tests using realtime ***®is highly sensitive and detects as little as 1 RNA copy perµL for real-time and endpoint RT-PCR,while using only half of the *** achieved comparable results with those of a commercial platform when detecting SARS-CoV-2 viruses from 81 clinical RNA ***®can also detect SARS-CoV-2 from 44 nasopharyngeal samples without RNA extraction by using a direct RT-PCR assay,which shortens the sample-to-answer time to an hour with minimal user ***,we validated the technology using an RT-LAMP assay on 54 clinical RNA ***,our platform provides a sensitive,cost-effective,and accurate diagnostic solution for lowresource settings.

关键词： fir confirmation diagnosis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

聚乙二醇脂质体阿霉素与托泊替康治疗复发难治性卵巢上皮癌患者的长期生存优势比较:3期随机研究

引用

世界核心医学期刊文摘（妇产科学分册） 2005年第2期1卷 42-42页

作者： gordon A.N. Tonda M. Rackoff W. 张剑萍

Provide long -term follow -up data fo r women treated in a randomized multicenter study of pegylated liposomal dox-orubicin compared with topotecan.P atients with epithelial ovarian cancer that recurred after o r failed to respond to firstline platinum -based chemotherapy were randomized to receive pegylated liposomal doxoru bicin 50mg /m 2 every28days(n =239)or topotecan 1.5mg /m 2 per day for 5days every 21days(n =235).Patients were stratified prospectively based on response to i nitial platinum -based chemotherapy as well as the presence or absence of bulky *** patients had been previously treated with platinum and taxanes(74%in the pegylated liposomal doxorubicin group and 72%in the topotecan group).Survival data are mature:87%of patients have died(n =413).There was an 18%reduction in the ris k of death for patients treated with pegy lated liposomal doxoru-bicin(median survival 62.7weeks for pegylated liposomal doxorubicin and 59.7weeks for topotecan -treated pa-tients;HR =1.216;95%confidence in terval(CI )1.000-1.478;P =0.050).The hazard ratio for all randomized subjects(includes those randomized,but never treated;n =481)was 1.23(median survival 63.6weeks for pegylated liposomal doxorubicin and 57.0weeks for topotecan -treated patients;95%CI 1.01-1.50;P =0.038).For patients with platinum -sensitive dis-ease,there was a 30%reduction in the risk of death for the pegylated liposomal doxorubicin -t reated group(median survival 107.9weeks for pegylated l iposomal doxorubicin and 70.1weeks for topotecan -treate d patients;HR =1.432;95%CI 1.066-1.923;P =0.017).In pa-tients with platinum -refractory di sease,survival was similar between treatment groups.L ong -term follow -up demonstrates that treatmentwith pegylated liposomal dox-orubicin significantly prolongs su rvival compared with topotecan in patients with recurren t and refractory epithelial ovarian *** survival benefi t is pronounced in pa-tients with platinumsensitive dise ase.

关键词：卵巢上皮癌托泊替康生存优势随机研究中位生存时间铂类药物铂类化疗药物肿瘤复发紫杉烷类研究机构

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：